EU News
 Printable version
|
Rift Valley fever: surveillance measures assessed
EFSA has completed its series of assessments on Rift Valley fever (RVF) with a scientific opinion looking at the effectiveness of surveillance and control measures in the EU.
The latest opinion follows two opinions published earlier this year which assessed respectively the risk of introduction of RVF to the EU and the impact of the disease in the French overseas department of Mayotte.
Background
Rift Valley fever is a vector-borne disease transmitted by mosquitoes to animals – domestic and wild ruminants and camels – and humans.
The disease is endemic in sub-Saharan Africa and in the Arabian Peninsula, but has never been reported in continental Europe although its range is expanding. In 2018-19 it reappeared after ten years in Mayotte, where there have been outbreaks involving multiple human cases.
Contacts
If you are a Journalist/Media representative, please contact our Media Relations Office. Otherwise, please use the Ask EFSA Service.
Media contacts
EFSA Media Relations Office
Tel. +39 0521 036 149
E-mail: Press@efsa.europa.eu
Other queries
